KRAS G12C inhibitors (G12Cis) have revolutionized the treatment of cancers driven by this historically undruggable mutation, offering unprecedented clinical responses in non-small cell lung cancer (NSCLC) and other malignancies. The gene discussed is KRAS; the disease is cancer.